StockData

Solesence vs cbdMD

SLSN and YCBD side by side, both in soap, detergents, and cleaning preparations; perfumes, cosmetics, and other toilet preparations. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SLSN and YCBD compare

Solesence is the larger company, worth 28 times as much as cbdMD ($113M against $4.1M).

cbdMD grew revenue faster over the last twelve months (10.0% versus −14.0% for Solesence).

Solesence keeps more of each dollar of sales as profit, with a net margin of −3.8% compared with −13.8% at cbdMD.

cbdMD scores higher on the StockData Score (10 against 7 for Solesence), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSLSNYCBD
Size and price
Market cap$113M$4.1M
Share price$1.60$0.363
Change, 1 year−2.4%−50.8%
Change, 5 years−57.1%−99.9%
Beta (5Y)3.792.28
Employees11542
StockData Score
Total score710 (better)
Valuation score13 (better)
Growth score11
Performance score11
Health score45 (better)
Dividend score00
Valuation
P/S2.0×0.2× (better)
P/B8.6×0.5× (better)
FCF yield–−59.2%
Fair value$1.68$2.01
Margin of safety5.0%82.0% (better)
Growth
Revenue growth (TTM)−14.0%10.0% (better)
Revenue growth, 5Y average29.4% (better)−14.5%
Net income growth (TTM)−134%–
EPS growth (TTM)−143%–
EPS growth, 5Y average−7.8%–
Profitability
Gross margin26.5%57.7% (better)
Operating margin−2.1% (better)−13.9%
Net margin−3.8% (better)−13.8%
FCF margin–−11.5%
Return on equity−15.1% (better)−40.3%
Return on invested capital−8.3% (better)−41.2%
Financial health
Debt / equity0.000.00
Current ratio0.972.50 (better)
Altman Z-score0.01 (better)−17.59
Piotroski F-score36 (better)
Dividends and buybacks
Buyback yield−0.09%–
Shareholder yield−0.09%0.00% (better)
Ownership
Held by institutions4.5%8.2%
Held by insiders75.2%34.6%
Insider net buying, 12 months$4.8K (better)−$1.3M
Short interest, % of float2.1%6.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.